Employers Struggle To Cope With the Rising Use of Biologies-Tradeoffs in cost sharing or higher deductibles could derail treatment and decrease the value of healthcare spending.

摘要

Employers are growing ever more concerned about the high cost of biologies and other specialty pharmaceuticals, but they can't reach a consensus on how they should deal with them when they design their benefit plans."Biologically based specialty pharmaceuticals account for, on average, less than 3.5 percent of an employer's total healthcare expenditures. In most organizations, only about 1 percent of individuals use biologies," says Frank Kopenski, principal and consulting actuary at Milliman.